Indivior Agrees to Pay $385M Amid Monopoly Lawsuit
October 27, 2023
Source: drugdu
84
Indivior, an addiction treatment company, announced that it has reached an agreement with wholesalers to resolve their claims of suppressing competition for its opioid addiction drug, Suboxone. As a result of the agreement, the upcoming trial, scheduled for Oct 30, has been cancelled. Reportedly, Indivior will pay $385 million and will take a charge of $228 million in the third quarter, which will be excluded from adjusted earnings.
“We are pleased to achieve this settlement to conclude this legacy multi-district antitrust matter,” said Mark Crossley, CEO, Indivior. “The resolution of this litigation, which was filed over a decade ago, provides greater certainty for all Indivior stakeholders and allows us to continue focusing on our important work for patients suffering from opioid use disorder and mental health illnesses around the world.”
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier April 29, 2024
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis April 29, 2024
- Merck plans €300m investment at new German research centre April 29, 2024
- Chiatai Tianqing’s Class 1 Innovative Drug TQA3038 (siRNA) Completes Phase I Clinical Study April 29, 2024
- Nestlé India and Dr Reddy’s announces joint venture April 29, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
